This is an automatically translated article.
Lopigim medicine contains the main ingredient Gemfibrozil and other excipients in sufficient quantities. The drug has an effective lipid-lowering effect and reduces the risk of coronary heart disease. In addition, Lopigim is used in the treatment of abdominal pain typical of pancreatitis, which has not responded to diet or other measures alone. However, the drug is not effective in the treatment of type I hyperlipidemia.
1. What is Lopigim? The effect of the drug Lopigim
Lopigim medicine contains the main active ingredient Gemfibrozil and excipients with sufficient drug content.
1.1. Pharmacodynamics of the drug Lopigim Lopigim is a drug for the treatment of dyslipidemia belonging to the fibrate group.
Mechanism of action of Lopigim:
Reduces the synthesis of LDL triglycerides in the liver by inhibiting peripheral lipolysis (reducing available fatty acids) and reducing the incorporation of long-chain fatty acids. Reducing the synthesis of LDL will reduce the formation of LDL (atherosclerosis-causing cholesterol) in which the marker apoprotein B is greatly reduced in the plasma; Increased HDL is associated with increased degradation of LDLs and increased synthesis of apoproteins AI and AII. Liver cholesterol clearance and biliary excretion are increased. In humans, Gemfibrozil has been shown to be effective when used as a single daily dose. Lopigim has an effect on platelet adhesion and aggregation. In humans, clinical studies have shown that a single daily dose of 900 mg Lopigim is effective:
Reduces levels of rapid triglycerides; Reduce total cholesterol index; Reduce LDL cholesterol index; Increases HDL cholesterol; Improves plasma cholesterol distribution by reducing the VLDL + LDL/HDL correlation (which is increased in atherosclerotic hyperlipidemia). 1.2. Pharmacokinetics of the drug Lopigim Absorption:
Gemfibrozil is rapidly absorbed from the gastrointestinal tract after drug use. The drug reaches its maximum concentration in the blood 1 to 2 hours after taking the drug. Plasma half-life: The plasma concentration is linearly related to the dose administered. The mean plasma half-life is about 1 hour 30. Metabolism and excretion:
Gemfibrozil is metabolized mainly by the liver. Lopigim is excreted mainly in the urine (70%), the drug is bound to proteins in about 97%. 1.3. The effect of the drug Lopigim Pharmaceutical substance Gemfibrozil is an anti-hyperlipidemic drug. Gemfibrozil drug reduces the concentration of triglyceride-rich lipoproteins such as VLDL (very low density lipoprotein), slightly increases the concentration of HDL (low density lipoprotein). The effect on VLDL concentrations may be primarily due to increased lipoprotein lipase activity, particularly in muscle, leading to increased hydrolysis of triglycerides in VLDL and increased catabolism in VLDL. Gemfibrozil also changes the composition of VLDL by reducing the liver production of apoC-III, which inhibits lipoprotein lipase activity and also reduces the synthesis of Triglycerides in VLDL in the liver. Along with the effect on blood lipids, Gemfibrozil also has the effect of reducing platelet aggregation, thus reducing the risk of cardiovascular diseases. Lopigim dosage forms:
Lopigim 300mg tablets; Lopigim tablets 600mg.
2. Indications of the drug Lopigim
Lopigim is indicated for use in the following cases:
People with type III hyperlipoproteinemia: Moderate and severe hypertriglyceridemia at risk of pancreatitis. Familial combined hyperlipidemia with high VLDL levels (additional low dose HMG CoA reductase inhibitor). Persons with hyperlipidemia and reduced risk of coronary heart disease in type IIb hyperlipidemia have no history or current symptoms of coronary heart disease, and have not responded to diet, exercise, weight loss, or use of the drug. taking another drug alone and having all 3 of the following symptoms: low HDL cholesterol, elevated LDL-cholesterol, and elevated triglycerides. People with types IV and V hyperlipidemia are at increased risk for coronary artery disease, abdominal pain typical of pancreatitis, unresponsive to diet.
3. How to use and dose Lopigim
How to use Lopigim:
Should take Lopigim with at least 30 - 50ml of filtered water, preferably boiled and cooled water. Avoid using Lopigim with carbonated drinks, alcohol, beer, milk. Take Lopigim 30 minutes before breakfast and dinner. Do not chew or crush Lopigim to avoid reducing or losing its effectiveness. Therapeutic dose of Lopigim:
Lopigim tablets 600 mg x 2 times/day. Lopigim should be discontinued after 3 months if serum lipoprotein levels do not improve significantly. Note when using the drug: The above treatment dose is for reference only. The specific treatment dose depends on the individual's condition and disease progression. To get the right dose for your body and medical condition, you need to consult your treating doctor or medical professional.
4. Undesirable effects of the drug Lopigim
Common undesirable effects:
Indigestion, flatulence, abdominal distension, abdominal pain, diarrhea, nausea, vomiting, constipation, acute appendicitis. Gallstones . Fatigue accompanied by dizziness, lightheadedness, headache. Skin signs: eczema, erythema. Uncommon side effects:
Atrial fibrillation. Hypersensitivity, dizziness, somnolence, somnolence, depression. Sensation. Feeling of blurred vision. Adverse effects were rare, not exceeding 1.3% of users (in clinical trials).
Digestive disorders : nausea, vomiting or a feeling of indigestion. Allergic reactions on the skin. Increased transaminases and bilirubin. Liver function should be monitored when using preparations containing Gemfibrozil. These disturbances resolve gradually when the drug containing Gemfibrozil is discontinued. Mild decrease in Hemoglobin, Hematocrit and white blood cells in the early stages when using Gemfibrozil, very rarely, severe anemia, leukopenia, severe thrombocytopenia and myelosuppression have occurred. Treatment doctors usually order periodic blood count tests during the first 12 months of treatment with Gemfibrozil-containing drugs. Note: This is not a complete list of Lopigim side effects. In the process of use may occur other adverse effects that have not been shown or have not been studied. If there are any other adverse effects of the drug not specified in the instructions for use, consult your treating doctor or medical professional.
5. Lopigim drug interactions
Anticoagulants, coumarin derivatives or indandion: Concomitant use with Lopigim may significantly increase the anticoagulant effect of these drugs; Your doctor will adjust your anticoagulant dose based on regular prothrombin time testing. Chenodesoxycholique or ursodesoxycholique: The effect may be reduced when these drugs are used concurrently with Lopigim, which tends to increase cholesterol saturation in the bile. Lovastatin: Concomitant use with Lopigim may increase the risk of rhabdomyolysis: a significant increase in creatine kinase levels, and myoglobinuria leading to acute renal failure; detectable as early as 3 weeks and as late as months after initiation of combination therapy; Creatin kinase monitoring does not prevent severe myopathy or kidney damage.
6. Some notes when using Lopigim
Initiate treatment: Perform tests to assess lipid levels. At the same time, before treatment, the doctor will prescribe to control serum lipids with appropriate diet, exercise, weight loss in obese people and control other diseases such as diabetes and hypothyroidism. During treatment: The treating physician will periodically test serum lipids. Discontinue use if the effect of the drug is not satisfactory after 3 months of treatment. After discontinuing treatment with Lopigim, an appropriate serum lipid-lowering diet should be instituted and serum lipids monitored until the patient is stable. If myositis is suspected or diagnosed, the drug should be discontinued. Note to other special groups:
Use for pregnant or lactating women: Consult your treating physician before using for pregnant or lactating women. Use for driving and operating machinery: Consult a doctor before intending to use the drug.
7. How to store Lopigim
Should store Lopigim at a temperature below 30 degrees Celsius. Store Lopigim in a cool place, away from direct sunlight. Do not leave Lopigim in wet places because it may cause mold and damage the medicine. Keep Lopigim out of reach of children and pets. The drug Lopigim contains the active ingredient Gemfibrozil and other excipients in a sufficient amount. The drug has an effective lipid-lowering effect and reduces the risk of coronary heart disease. In addition, Lopigim is used in the treatment of abdominal pain typical of pancreatitis, which has not responded to diet or other measures alone. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
